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Abstract
The skin of an adult human contains approximately 20 billion memory T cells. Epithelial barrier 
tissues are infiltrated by a combination of resident and recirculating T cells in mice but the relative 
proportions and functional activities of resident versus recirculating T cells have not been 
evaluated in human skin. We discriminated resident from recirculating T cells in human engrafted 
mice and lymphoma patients using alemtuzumab, a medication that depletes recirculating T cells 
from skin, and then analyzed these T cell populations in healthy human skin. All non-recirculating 
resident memory T cells (TRM) expressed CD69, but the majority were CD4+, CD103− and 
located in the dermis, in contrast to studies in mice. Both CD4+ and CD8+ CD103+ TRM were 
enriched in the epidermis, had potent effector functions and had a limited proliferative capacity 
compared to CD103− TRM. TRM of both types had more potent effector functions than 
recirculating T cells. Induction of CD103 on human T cells was enhanced by keratinocyte contact, 
depended on TGFβ and was independent of T cell keratinocyte adhesive interactions. We observed 
two distinct populations of recirculating T cells, CCR7+/L-selectin+ central memory T cells (TCM) 
and CCR7+/L-selectin− T cells, which we term migratory memory T cells (TMM). Circulating 
skin-tropic TMM were intermediate in cytokine production between TCM and effector memory T 
cells. In patients with cutaneous T cell lymphoma, malignant TCM and TMM induced distinct 
inflammatory skin lesions and TMM were depleted more slowly from skin after alemtuzumab, 
suggesting TMM may recirculate more slowly. In summary, human skin is protected by four 
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functionally distinct populations of T cells, two resident and two recirculating, with differing 
territories of migration and distinct functional activities.
Introduction
Research in both mice and humans has confirmed that skin and other epithelial barrier 
tissues are populated by a combination of non-recirculating resident memory cells (TRM) as 
well as T cells that recirculate in and out of tissues (1, 2). However, the relative proportions 
and functional activities of resident and recirculating T cells in skin have never been 
comprehensively studied, especially in humans. TRM cause psoriasis and mycosis fungoides 
and are implicated in a variety of other human autoimmune and inflammatory conditions 
(3). A better understanding of resident and recirculating T cells could lead to novel therapies 
for T cell mediated inflammatory diseases.
Our prior studies of patients with cutaneous T-cell lymphoma (CTCL) found that treatment 
with alemtuzumab, a humanized anti-CD52 antibody, depleted all circulating T cells and 
purged the skin over time of recirculating T cells but spared a population of non-
recirculating TRM in the skin (2). Alemtuzumab depletes T cells in the blood stream but not 
in the skin because it depletes by antibody dependent cellular cytotoxicity (ADCC) requiring 
the presence of neutrophils and/or NK cells, cell types that are rare in human peripheral 
tissues such as the skin but frequent in the circulation (2, 4).
In these studies, we have studied resident and recirculating T cell subsets in a human 
engrafted mouse model and in human patients with CTCL, utilizing alemtuzumab as a tool 
to deplete recirculating T cells from skin. This has allowed us to discriminate between 
resident and recirculating T cell populations in human skin and to study their relative 
frequencies and effector functions. We find that human skin is protected by two distinct 
populations of recirculating T cells and two distinct populations of resident memory T cells, 
each with different functional capacities.
RESULTS
Skin T cells in a human engrafted mouse model recapitulate T cell populations in healthy 
human skin
In order to selectively study recirculating and resident T cells in human skin in an accessible 
model, we grafted NSG mice with human neonatal foreskin, infused them IV with 
allogeneic PBMC, allowed a dermatitis to develop and then treated these mice with 
alemtuzumab to deplete recirculating T cells from skin (Fig. 1A). Neonatal foreskin was 
used in these studies because, based on mouse studies showing that TRM are generated in 
skin following cutaneous infections, we suspected neonatal human foreskin would have few 
resident memory T cells (1, 5, 6). This was in fact the case. Human neonatal foreskin 
contained resident antigen presenting cells (APC) including CD1a+ Langerhans cells and 
CD11c+ dendritic cells (DC, Fig. 1B,C) but had very few T cells (Fig. 1C,D). There were 
four-fold more CD11c+ DC than T cells in neonatal foreskin (Fig. 1C) and 45-fold fewer T 
cells in foreskin than in healthy adult human skin (Fig. 1D). Additionally, T cells isolated 
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from foreskin lacked expression of the TRM markers CD69 and CD103, which were robustly 
expressed by a subset of T cells from adult human skin (Fig. 1E). Neonatal foreskin was 
therefore a excellent source of T cell depleted human skin in which the migration and 
differentiation of newly generated TRM could be studied. Allogeneic T cells injected IV into 
grafted mice migrated specifically into the human skin graft and educed an inflammatory 
dermatitis characterized by migration of T cells into both the dermis and epidermis (Fig. 1F–
H). In contrast, mice grafted with human foreskin but not injected i.v. with allogeneic T cells 
lacked inflammation (Fig. 1I). T cells were evident within the graft by week 1 after infusion 
and the T cell infiltrate was maximal by week 3 (Supp. Fig. 1). In mice, TRM generated by 
viral infections with HSV and vaccinia virus co-expressed CD69 and CD103 (5, 6). A subset 
of T cells infiltrating the human skin graft up-regulated CD69 and CD103 after migration 
into the graft (Fig. 1J). CD69 was expressed within in the first week after T cell entry into 
the graft but up-regulation of CD103 was slower and peaked at week three (Fig. 1J). We 
compared the T cells in foreskin grafts with those isolated from healthy adult human skin, a 
tissue known to contain both skin-tropic CCR7+/L-selectin+ central memory cells (TCM) and 
non-recirculating TRM (2, 7). Grafts from mice contained CCR7+/L-selectin+ skin tropic T 
and TCM cells that expressed CD69 and CD103 in proportions similar to those isolated from 
antigen-experienced adult human skin (Fig. 1K). A population of CD69+ T cells that lacked 
CD103 expression, a subset not reported in mice, was also observed in skin grafts and in 
healthy human skin (Fig. 1K). The percentages of T cells expressing CD69 and CD103 in 
the grafted skin was not significantly different from the percentages expressed by T cells 
from healthy adult human skin (Fig. 1L).
Alemtuzumab depletes recirculating TCM from skin grafts but spares a population of T 
cells in skin
Our previous studies in human CTCL patients treated with alemtuzumab demonstrated that 
this medication depleted T cells in blood and purged the skin of recirculating T cells over 
time but spared a population of non-recirculating resident memory T cells in skin (2). 
Similar to our results in CTCL patients, treatment of foreskin-grafted, PBMC-injected mice 
with alemtuzumab depleted circulating T cells from the blood but spared a subpopulation of 
T cells in skin (Fig. 2A,B). In contrast, A-dmDT(390)-bisFv(UCHT1), a recombinant 
immunotoxin composed of diphtheria toxin conjugated to anti-CD3, completely depleted T 
cells in both blood and skin (Fig. 2A,B). In CTCL patients, alemtuzumab depleted the skin 
of recirculating CCR7+/L-selectin+/ central memory T cells (TCM), a population that is also 
observed in healthy skin (2, 7). Likewise, alemtuzumab depleted both CD4+ and CD8+ TCM 
from skin grafts on human engrafted mice (Fig. 2C,D).
Distinct populations of non-recirculating TRM exist in human engrafted mice and human 
skin
Having established that the cell populations in human engrafted mice were comparable to 
those in healthy human skin and that alemtuzumab depleted recirculating T cells in this 
model as it did in human patients (Figs.1,2), we set out to study the non-recirculating TRM 
populations left within the human skin grafts after alemtuzumab treatment. The vast 
majority of TRM remaining in skin after alemtuzumab depletion of recirculating T cells 
expressed CD69+ and a subset coexpressed CD103 (Fig. 3A). In human engrafted mice, 
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CD4+ T cells were four-fold more frequent than CD8+ T cells both before and after 
depletion of recirculating T cells with alemtuzumab, suggesting that CD4 cells 
predominated in both the recirculating and resident T cell populations in this model (Fig. 
3B). Approximately half of CD8+ TRM expressed CD103 but the majority of CD4+ TRM did 
not (Fig. 3C). When TRM were evaluated as a whole, the most frequent population were 
CD4+ CD103− T cells, which made up approximately 66% of the total TRM population (Fig. 
3D). CD8+ T cells made up 17% of the TRM population and only 26% of the total TRM 
population expressed CD103. CD69+ T cells were evident in both the epidermis and dermis 
of grafts from alemtuzumab treated human engrafted mice and only a subset of these T cells, 
in both the epidermis and the dermis, coexpressed CD103 (Fig. 3E). In order to confirm 
these results in human patients, we studied the T cells remaining in the skin of CTCL 
patients after alemtuzumab therapy. We found that, similar to results in human engrafted 
mice, TRM remaining in skin after alemtuzumab virtually all expressed CD69 and a subset 
of both CD4 and CD8 T cells co-expressed CD103 (Fig. 3F). In addition, a small population 
of L-selectin+CCR7− existed in human engrafted mice, healthy skin, and the skin of CTCL 
patients (Figs. 2C, S3A, E–F). These cells were not depleted by alemtuzumab and co-
expressed CD69, suggesting they are TRM (Figs. 2C, S3A, E–F).
Antigen experienced human skin contains two phenotypically and functionally distinct 
populations of TRM
Studies in human engrafted mice and alemtuzumab treated CTCL patients demonstrated 
there were two distinct populations of CD69+ non-recirculating TRM in skin, one that 
expressed CD103 and one that did not. However, the relative percentages and effector 
functions of cells in the mouse model and in patients with a Th2 biased T-cell lymphoma 
were unlikely to reflect those observed in healthy human skin (8–11). We therefore 
extracted and studied the T cells from healthy adult human skin, a tissue in which TRM have 
presumably accumulated over many years of infections and antigen exposures.
In mouse skin, the most frequently observed and well described TRM subset are 
intraepithelial CD8+ CD103+ T cells and T cells of this phenotype have also been observed 
after HSV infection in humans (5, 6, 12, 13). In order to study the location and proportion of 
TRM in human skin, we enzymatically split skin into epidermis and dermis and isolated the 
T cell populations by collagenase digestion (Fig 4A–C). CD4+ and CD8+ T cells co-
expressing CD69 and CD103+ were evident in both the epidermis and the dermis, although 
CD103+ TRM of both subsets were more frequent in the epidermis. CD69+CD103− TRM 
were more prevalent in the dermis and both CD4+ and CD8+ T cells had this phenotype. 
CD69− T cells, referred to as recirculating T cells, were the least frequent T cell population 
in both the epidermis and the dermis (Fig. 4B,C).
We next studied the functional capacities of TRM and recirculating subsets from whole skin, 
epidermis and dermis. In general, cytokine production by the two distinct TRM subsets was 
greater than observed in recirculating T cells, consistent with their role as resident immune 
sentinels (Fig. 4D). Effector cytokine production by CD103+ TRM also tended to be more 
robust than in CD103− TRM, most notably with respect to production of IFNγ,TNFα and 
IL-22. Taken together, these results demonstrate that two phenotypically and functionally 
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distinct populations of TRM exist in both the CD4+ and CD8+ T cell compartments in human 
skin. CD103+ T cells were enriched in the epidermis and had a tendency for increased 
effector cytokine production, whereas CD103− TRM were more frequent in the dermis and 
had slightly lower but still very potent effector functions when compared to recirculating T 
cells.
In order to study the relative proliferative capacity of the two TRM subsets in healthy skin, 
we first isolated T cells from the epidermis and dermis as CD103 enriched and depleted 
populations respectively. T cells isolated from the epidermis retained CD103 expression but 
rapidly lost functional activity and underwent apoptosis after removal from the skin 
environment, similar to the behavior of CD103+ TRM isolated from mouse brain after 
infection with vesicular stomatitis virus (14) (Fig. S2A–E). In order to study antigen 
responses and proliferative capacity without removing T cells from skin, we injected 
stimulatory anti-CD3 and anti-CD28 antibodies or antigen derived from heat killed Candida 
albicans or Staphylococcus aureus directly into explants of human skin. Injected skin 
explants were cultured for 2 weeks after which T cells were collected. Proliferation was 
assayed by staining for Ki-67 and cytokine production was assayed by intracellular flow 
cytometry following short-term stimulation with PMA and ionomycin (Fig. 5). In both 
CD4+ and CD8+ T cells, proliferation was greatest in the CD103 − TRM subset in response 
to both antibody and antigen stimulation, although differences only reached significance in 
CD4+ T cells (Fig. 5A,C). Production of TNFα tended to be greater in the CD103+ 
population (Fig. 5B,D). Taken together, these studies suggest that CD103+ TRM had superior 
effector functions but a limited proliferative capacity.
T cell CD103 induction is enhanced by keratinocyte contact, depends on TGFβ and is 
independent of T cell keratinocyte adhesion
In mouse models of viral skin infection, CD103 expression by T cells required entry into the 
epidermis and depended on TGFβ (15, 16). In human engrafted mice, T cells that had 
migrated into the epidermis had a higher rate of CD103 positivity than dermal T cells (Fig. 
6A,B). To determine if keratinocyte contact can induce human T cell CD103 upregulation, 
we cultured T cells stimulated with αCD3/αCD2/αCD28 beads on keratinocyte or 
fibroblasts monolayers either in direct contact or separated by transwells. CD103 
upregulation was enhanced by direct contact with keratinocytes (Fig. 6C). To determine if 
adhesive interactions between T cells and keratinocytes participated in the signaling required 
for induction of CD103, we included function blocking antibodies against E-cadherin, 
LFA-1 and β1 integrins in T cell and keratinocyte monolayer cultures (Fig. 6D). Blocking 
adhesive interactions had no effect on CD103 upregulation but neutralizing antibodies 
against TGFβ decreased CD103 induction. Additional studies in transwells and in direct co-
cultures demonstrated that neutralization of TGFβ decreased the CD103 upregulation 
induced by keratinocyte contact and that recombinant human TGFβ markedly increased 
CD103 induction in both the presence and absence of contact with keratinocytes (Fig. 6E,F). 
Although adhesive interactions between keratinocyte E-cadherin and CD103 did not 
participate in stimulating CD103 induction, these interactions did function to anchor T cells 
to keratinocyte monolayers.
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Human skin also contains two distinct populations of recirculating memory T cells
We had previously reported that healthy human skin was patrolled by a skin tropic 
population of central memory T cells that co-expressed both skin homing receptors (CLA/
CCR4) and central memory markers (CCR7/L-selectin) and were depleted by alemtuzumab 
therapy (2). However, when reviewing our results, we observed that both healthy skin and 
the skin of CTCL patients contained a distinct population of CCR7+/L-selectin− T cells (Fig. 
7A,B). CCR7+/L-selectin− T cells were confined to the dermis and absent from the 
epidermis (Fig. S3A). Approximately a third of CCR7+/L-selectin− T cells co-expressed 
CD69, suggesting they may be T cells in a transitional state, but the remaining CCR7+/L-
selectin−/CD69− T cells made up a significant proportion of T cells in both healthy skin and 
in CTCL patients (Fig. 7B). These T cells were depleted in CTCL patients by alemtuzumab 
therapy, demonstrating that they represent a recirculating T cell population (Fig. 7A,B). In 
mice, CCR7 expression is required for exit from peripheral tissues via lymphatics and a 
recirculating population of CD4+/CCR7+/ L-selectinlo T cells was found in Kaede mice to 
recirculate out of skin in a CCR7-dependent manner (17–19). CCR7+/L-selectin− cells, 
which we will refer to as migratory memory T cells (TMM), were present in similar 
proportions in both healthy skin and among the benign, nonmalignant T cells in patients 
with CTCL and these cells were completely depleted by alemtuzumab therapy (Fig. 7B). 
TMM made up the majority of both CD4+ and CD8+ CLA+ skin tropic T cells in the blood of 
healthy human donors, confirming that T cells do recirculate between the blood and skin 
(Fig. 7C, representative histograms in Fig. S4). We next isolated skin tropic (CLA+) TCM, 
TMM and effector memory T cells (TEM) from human blood and compared their relative 
functional capacities after stimulation with PMA and ionomycin followed by comprehensive 
cellular phenotype by CyTOF mass cytometry (Fig. 7D). In general, effector cytokine 
production by TMM was intermediate between that of TEM and TCM. Interestingly, 
production of Th1, Th17 and Th22 proinflammatory effector cytokines was highest in TEM, 
but Th2 cytokine production (IL-4 and IL-13) was highest in TCM. TNFα was produced at 
high levels by all T cell subsets. Although not significantly different, IL-2 production, 
previously reported as a feature of TCM that may render them resistance to apoptosis, tended 
to be higher in the recirculating TCM and TMM populations than in TEM (20).
TMM are associated with the development of expanding skin lesions in patients with CTCL 
and are depleted from skin more slowly than TCM
CLA+ skin tropic CCR7+/L-selectin− TMM clearly recirculate between human blood and 
skin, as evidenced by their presence in both sites and their depletion by alemtuzumab in 
patients with CTCL. TMM leaving skin via the lymphatics would be expected to enter skin 
draining lymph nodes and eventually re-enter the circulation via the thoracic duct. However, 
these cells lack L-selectin and likely cannot access lymph nodes from blood the way naïve T 
cells and TCM are thought to, by migrating across high endothelial venues (21, 22). Instead, 
these T cells would be expected to home directly back to skin. In order to study the biologic 
behavior of these cells in human beings in vivo, we studied CTCL patients with malignant T 
cells that expressed markers of TMM. We have previously observed that patients with classic 
Sézary syndrome, composed of the clinical triad of diffuse erythema of the skin, 
enlargement of the lymph nodes draining both skin and other organs and circulating 
malignant T cells in the blood, have malignant T cells with the phenotype of skin tropic 
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central memory T cells (2, 23). CLA+ TCM would be expected to recirculate between the 
skin, blood and lymph nodes according to our current understanding of trafficking, and this 
is precisely where malignant T cells accumulate in Sézary patients. Moreover, we found that 
malignant T cells of a CLA+ TCM phenotype induced in patients a diffuse erythema of the 
skin, and that this diffuse erythema was the best clinical predictor of complete remission in 
response to alemtuzumab therapy (Fig. 8A)(24). However, patients have a myriad of clinical 
presentations and we have found that some patients present with erythematous skin lesions 
that have ill-defined borders, in contrast to patients with Sézary syndrome, who present with 
diffuse erythema, and patients with mycosis fungoides (MF), who present with fixed, 
recurrent and sharply demarcated inflammatory skin lesions (Fig. 8). We found that patients 
with malignant T cells that had the phenotype of CCR7+/L-selectin− TMM tended to have 
only involvement of the lymph nodes draining the skin and to have expanding inflammatory 
skin lesions with ill-defined borders. (Fig. 8B–D). In one patient, the malignant T cells in 
blood and skin were a combination of both TCM and TMM. This patient had a background of 
diffuse erythema as well as more discrete skin lesions on presentation (Figure 8E). After 18 
days on alemtuzumab, re-biopsy of the skin demonstrated that TCM had been partially 
depleted but large numbers of TMM remained in the skin. This was associated with 
resolution of the diffuse erythema but persistence of the erythematous skin lesions. Taken 
together, the lack of lymph node disease, the clinical appearance of these lesions and the fact 
that TCM were depleted more rapidly from the skin then TMM after alemtuzumab therapy 
suggest that TMM do recirculate between the blood and skin, are excluded from the lymph 
nodes, and may recirculate more slowly than TCM.
Discussion
The skin surface of a healthy adult human being contains nearly 20 billion diverse memory 
T cells with potent effector functions (7). Our previous studies in alemtuzumab treated 
CTCL patients demonstrated that human skin contains a combination of resident and 
recirculating memory T cells but the relative frequencies and functional activities of the 
subsets remain uncharacterized (2). In the current studies, we used alemtuzumab as a tool to 
deplete recirculating T cells from skin in order to discriminate between recirculating and 
resident memory T cell populations.
We developed a human engrafted mouse model to study human resident and recirculating T 
cell populations in skin. Immunodeficient mice were grafted with human neonatal foreskin, 
a tissue that contains resident Langerhans cells and DC but has few T cells. The paucity of 
resident T cells in the graft allowed us to be more confident that T cells observed in the skin 
after allogeneic i.v. PBMC infusion were derived from the i.v. injected T cells. TRM are 
normally generated as a result of cutaneous infections. We took advantage of the fact that 
graft resident APC were likely to activate T cells migrating into the graft from the blood via 
direct allo-recognition, a direct recognition of MHC I and II by allogeneic CD8+ and CD4+ 
T cells, respectively. Direct allo-recognition induces a robust polyclonal T cell response, 
engaging up to 10% of T cells (25). In other words, we utilized the allogeneic T cell 
response to engage the T cell receptor and initiate the TRM differentiation program within 
grafted skin. We observed the development of CD69+ and CD103+ T cells in grafted skin in 
proportions that were similar to those in adult human skin. However, antigen recognition of 
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allogeneic tissues is likely ongoing in human engrafted mice and some CD103− T cells may 
be in the process of transitioning to CD103+ TRM.
We next treated these mice with alemtuzumab in order to discriminate between recirculating 
and resident memory T cell subsets. Similar to our previous results in CTCL patients treated 
with alemtuzumab, alemtuzumab purged the skin of recirculating TCM but spared a 
population of T cells in skin. In contrast, immunotoxin A-dmDT (390)-bisFv(UCHT1), an 
anti-CD3 recombinant diphtheria immunotoxin currently in trials for the treatment of CTCL, 
depleted T cells completely in both blood and skin of grafted mice (26).
We observed that virtually all T cells remaining in the skin of grafted mice following 
alemtuzumab expressed CD69 and similar results were observed in alemtuzumab treated 
CTCL patients. In mice, nonrecirculating TRM generated from experimental infections 
expressed CD69 and populations of T cells in human peripheral tissues have been shown to 
express this marker as well (1, 7, 27). CD69 suppresses the activity of sphingosine 1 
phosphate receptor 1 (S1P1) and S1P1 down-regulation in mice was found to be necessary 
for retention of CD8+ TRM in skin (16, 28). However, it has never been conclusively 
demonstrated in humans that CD69 identifies the non-recirculating T cell pool in peripheral 
tissues. Our studies in human engrafted mice and in human patients treated with 
alemtuzumab demonstrate that CD69 is an excellent marker for nonrecirculating TRM in 
human skin.
Most of the TRM generated by viral infections in mice are sessile CD8+ T cells expressing 
CD69 and CD103 localized to the epithelium, although dermal CD4+ TRM with more 
mobility have also been observed following HSV infection (1, 5, 6, 29). Our studies in 
engrafted mice, CTCL patients and healthy human skin demonstrate that the majority of 
human skin TRM are dermal CD4+ T cells that lack CD103 expression. However, we do find 
that CD103+ T cells, both CD4+ and CD8+, are enriched in the epidermis. With respect to 
their functional capacities, CD103+ TRM had more potent effector functions but a poorer 
proliferative capacity. T cells isolated from the epidermis, which are enriched for CD103+ 
TRM, rapidly underwent apoptosis when removed from the skin microenvironment and had a 
poor proliferative capacity; these findings are very similar to the behavior of CD103+ TRM 
isolated from the brains of mice following infection with vesicular stomatitis virus (14).
Upregulation of CD103 by skin T cells in mouse models has been shown to occur after entry 
into the epidermis and to depend on TGFβ (15). A second study suggested IL-33 and TNFα 
may also contribute (16). We observed in human engrafted mice that T cells that had 
migrated into the epidermis had higher levels of CD103 than dermal T cells. Hypothesizing 
that contact with keratinocytes might participate in CD103 upregulation, we found that 
direct culture of stimulated blood T cells with keratinocyte monolayers enhanced CD103 
expression in a manner that was TGFβ dependent but did not require adhesive interactions 
between T cells and keratinocytes. Moreover, exogenous TGFβ markedly enhanced CD103 
induction in the presence or absence of direct keratinocyte contact. Although signaling from 
integrin and CD103-E-cadherin mediated adhesive interactions did not enhance CD103 
upregulation, CD103-E-cadherin interactions did serve to tether T cells to keratinocyte 
monolayers. Taken together, these studies suggest that CD103 in human T cells is 
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upregulated by TGFβ produced within the epidermal compartment. Although adhesive 
interactions with keratinocytes do not induce CD103 upregulation, CD103 likely participates 
in tethering T cells within the epidermal compartment.
In summary, we find that human skin is populated by a combination of CD103+ and 
CD103− TRM, with CD4+ TRM predominating. The preponderance of CD4+ TRM in human 
skin may reflect the diversity of antigen exposures encountered by individuals throughout 
their lifetimes. Most mouse models of TRM generation utilize viruses to induce TRM 
formation, including HSV and vaccinia infection, and these mice are kept in pathogen free 
barrier conditions to prevent other infections (5, 6). In contrast, our healthy adult human skin 
donors will have been exposed to a combination of viral, bacterial, fungal and possibly 
parasitic infections. It is worth noting that the antigen specificities of human skin TRM are a 
valuable immunologic record of what infectious pathogens and antigens an individual has 
been exposed to during his or her lifetime. Moreover, encoded within the cytokine and 
effector functions of these T cells is a history of how these individuals overcame each 
pathogen. There are currently no techniques that allow us to extrapolate antigen specificity 
from the sequences of the TCR receptor. However, once such techniques are developed, we 
will be able to investigate the immunologic history of an individual from the T cells 
remaining in their skin. Recent studies in mice showed that skin antigen exposures led 
individual naïve T cells to differentiate into roughly equal numbers of skin resident TRM and 
recirculating TCM, suggesting that immune reactions in skin generate TCR identical resident 
and recirculating T cell subsets (30).
We identified recirculating T cell subsets by studying the populations of T cells that were 
depleted from skin by alemtuzumab. Our prior work in patients with leukemic CTCL (L-
CTCL) treated with alemtuzumab found that human skin and the skin of CTCL patients 
contained a population of T cells that coexpressed both skin homing addressins (CLA/CC4) 
and central memory markers (CCR7/L-selectin) (2). In fact, in many patients with L-CTCL, 
malignant T cells had this phenotype (23). Alemtuzumab depleted these T cells from blood 
and purged them from the skin over time as well, confirming that they recirculate. TCM, as 
first described, were thought to be a subset of T cells that recirculated between the blood and 
lymph nodes and lacked tissue tropism (20). However, skin tropic TCM exist in both the skin 
and blood in humans and would be expected to recirculate actively between the lymph 
nodes, blood and the skin. Indeed, a similar population of recirculating T cells was identified 
in the skin of Kaede mice (17). These T cells expressed co-expressed CCR7 and L-selectin 
at intermediate levels and recirculated between the blood, skin, and both skin draining and 
distant lymph nodes. These T cells had quantitatively lower levels of L-selectin expression 
than T cells from the circulation but expression was sufficient to allow these cells to 
recirculate through noncutaneous, distal lymph nodes (17). Because these T cells could 
access systemic lymph nodes, we believe they represent the analogous population in mice to 
cells we refer to as skin tropic TCM.
We also found evidence for an additional population of CCR7+/L-selectin− recirculating T 
cells in human skin, which we refer to as migratory memory T cells (TMM). This population 
of recirculating T cells was poorly reproduced in our engrafted mouse model but was 
present in the blood and skin of healthy individuals and CTCL patients and was depleted by 
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alemtuzumab therapy. In humans, CLA+ TMM were the most prevalent subset of CLA+ 
memory T cells in the blood. TMM would presumably be excluded from lymph nodes 
draining noncutaneous tissues because they lacked L-selectin. However, they would access 
skin draining lymph nodes as they migrated out of the skin into the lymphatics and from 
there into skin draining lymph nodes. We found support for this concept in the clinical 
findings thatpatients with CTCL and TMM malignant T cells tended to have enlargement of 
only skin draining lymph nodes (termed dermatopathic nodes) but lacked diffuse lymph 
node involvement, a feature often observed in L-CTCL patients with TMM malignancies.
With respect to their functional capacities, TMM were intermediate between TCM and TRM in 
their production of inflammatory cytokines. Interestingly, we found that Th2 cytokine 
production was enriched in recirculating T cells (TMM and TCM) but that the production of 
Th1, Th2 Th17 and Th22 associated inflammatory cytokines was enriched in effector 
memory T cells (TEM). IL-2 was expressed at higher levels by recirculating T cells, 
consistent with a possible role for this cytokine in preventing apoptosis and maintaining cell 
viability during their turbulent and continual migration through the bloodstream and tissues.
Although the data we have are limited, our findings in human patients treated with 
alemtuzumab suggest TMM may recirculate more slowly through skin than TCM. CTCL 
Patients with malignant T cells of a TMM phenotype developed ill-defined but discrete skin 
lesions, whereas L-CTCL patients with malignant T cells of a TCM phenotype had diffuse, 
often complete erythema of the skin (erythroderma). We hypothesize that the diffuse 
erythema caused by malignant TCM arises from the rapid migration of these cells in and out 
of skin and also within the skin itself. In contrast, TMM gave rise to ill-defined but discrete 
skin lesions, consistent with a slower migration of these T cells in and out of skin and within 
the skin itself. Moreover, in the one patient we were capable of studying, TMM were 
depleted more slowly from the skin than TCM. However, an alternative explanation may be 
that TMM may be the subset of T cells that give rise to TRM. In this case, the skin lesions we 
see developing these patients may represent TMM differentiating in situ into TRM at the sites. 
The continued development of new expanding skin lesions in these patients likely results 
from recirculating TMM entering new areas of skin from the blood stream and initiating new 
lesions. Whether the skin lesions generated by TRM represent newly generated TRM or 
simply a slower migration of TMM through skin remains to be determined. Lastly, it is not 
clear why TMM are underrepresented in human engrafted mice. One possibility is that TMM 
may be a major source of TRM and are therefore depleted as TRM develop in the skin. A 
second possibility is that the subset of human T cells may not survive well within the mouse 
microenvironment.
One caveat to our findings is that although we and other groups studying resident and 
recirculating T cell populations use designations such as TRM and TCM to describe subsets 
of T cells, markers such as CD69 and CCR7 that are used to define these putatively stable 
subsets can change with T cell activation. Additional work will be needed to identify exactly 
how stable these T cell subsets are and to identify additional, less variable surface markers 
to identify them.
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In summary, we present a thorough characterization of resident and recirculating memory T 
cells in human skin. We find that two discrete populations of TRM are stationed in human 
skin and two distinct populations of T cells recirculate through skin. Each of these subsets 
has distinct recirculation and functional capacities and each is likely to play a unique role in 
protection against known pathogens. Both TRM and recirculating T cells are known to 
contribute to human diseases. For example, psoriasis is a disorder of dysregulated TRM and 
L-CTCL represents a malignancy of recirculating T cells (23, 31–33). Recent findings in 
mice that TRM and recirculating T cells have very different patterns of gene expression 
highlight the fact that these cell types have a very distinct biology (15). Excepting the 
current study, the relative proportions of resident and recirculating T cells in human tissues 
remain uncharacterized. Moreover, the contribution of TRM vs. recirculating T cells to most 
human inflammatory and autoimmune diseases and the effects of anti-inflammatory 
therapies on these T cell subsets are unknown. A better understanding of these resident and 
recirculating T cell subsets is therefore critical to understand healthy immune responses and 
identify therapies that preferentially target pathogenic T cells in autoimmune and 
inflammatory diseases.
Materials and Methods
Study design / Experimental design
This is an experimental laboratory study performed on human tissue samples. All studies 
were performed in accordance with the Declaration of Helsinki. Blood from healthy 
individuals was obtained after leukapheresis, skin was obtained from healthy patients 
undergoing cosmetic surgery procedures. Blood and lesional skin from patients with CTCL 
were obtained from patients seen at the Dana-Farber/Brigham and Women’s Cancer Center 
Cutaneous Lymphoma Program. L-CTCL and MF patients described in this manuscript met 
the WHO-EORTC criteria for L-CTCL/SS or MF (34). All tissues were collected with prior 
approval from the Partners and Dana Farber Institutional Review Board. Enumeration of T 
cell subsets in immunofluorescence studies was done in an investigator blinded fashion. 
Mechanistic studies on cells derived from blood and human tissues were performed using in 
vitro assays without blinding or randomization. Study components were not predefined.
Human engrafted mouse model
Human neonatal foreskins were grafted onto the backs of 6- to 8-week-old NOD/SCID/IL-2 
receptor γ chainnull mice (Jackson Laboratories). One week later 5 x 106 allogeneic PBMC 
were injected i.v. after isolation from healthy donors by ficoll centrifugation. Antibody 
injections commenced 2–4 weeks after PBMC engraftment. Alemtuzumab (2.5 μg) or 
isotype control (human IgG1, Biolegend) was injected i.p. 3 times/week for 3 weeks. Anti-
CD3-diphtheria toxin (A-dmDT(390)-bisFv(UCHT1), 0.625 μg) or isotype control (human 
IgG1) was injected i.v. once/day for 4 days. At the conclusion of the experiment, blood and 
skin grafts were harvested for analysis by flow cytometry, immunofluorescence and/or 
hematoxylin/eosin staining.
Watanabe et al. Page 11
Sci Transl Med. Author manuscript; available in PMC 2015 September 18.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Skin and blood samples
The protocols of this study were performed in accordance with the Declaration of Helsinki, 
and were approved by the Institutional Review Board of the Partners Human Research 
Committee (Partners Research Management). Skin from healthy patients was obtained from 
patients undergoing cosmetic surgery procedures and blood from healthy individuals was 
obtained as discarded tissue following leukopheresis. Neonatal foreskins were obtained from 
infants undergoing circumcision at the Brigham and Women’s Hospital. Blood and lesional 
skin from patients with CTCL were obtained from patients seen at the Dana-Farber/Brigham 
and Women’s Cancer Center Cutaneous Lymphoma Program. L-CTCL and MF patients 
described in this manuscript met the WHO-EORTC criteria for CTCL. PBMC were isolated 
by ficoll centrifugation.
T cell isolation from skin
Full thickness human skin samples, fresh or after engraftment on mice, were extensively 
minced and then incubated for 2 hours at 37°C in RPMI 1640 containing 0.2% collagenase 
type I (Life Technologies) and deoxyribonuclease I (30 Kunitz units/ml, Sigma Aldrich). 
Thereafter, cells were collected by filtering the collagenase-treated tissue through a 40-μm 
cell strainer. For some experiments, epidermis and dermis were separated by overnight 
incubation in dispase II (1.4 IU/ml, Roche Diagnostics) at 4°C followed by mechanical 
separation. Epidermis was then minced and incubated with dispase for an additional 30 min 
at 37°C with agitation followed by filtration through a 40-μm cell strainer. Dermis was 
minced and treated with collagenase as per full thickness skin protocol. Cells from whole 
skin, dermis or epidermis were incubated at 37°C for 2 days in Iscove’s DMEM 
supplemented with 20% fetal bovine serum, penicillin/streptomycin, glutamine and 2-
mercaptoethanol prior to flow cytometry analysis. When indicated (Fig. S2), the pan-caspase 
inhibitor Z-VAD-FMK (R&D Systems) was included at low (10 μM) or high (100 μM) 
concentrations to inhibit apoptosis.
Flow cytometry
Analysis of T cells was performed using directly conjugated monoclonal antibodies obtained 
from BD Biosciences, eBioscience, Biolegend, Beckman Coulter or R&D Systems.. Isotype-
matched negative control antibodies were used to set the gates for positive staining. For 
analysis of cytokine production, T cells were stimulated with either control medium or 50 
ng/ml PMA (Sigma Aldrich) and 750 ng/ml ionomycin (Life Technologies) plus 10 μg/ml 
Brefeldin A (BD Biosciences) for four hours. Cells were surface stained, fixed, 
permeabilized, stained with anti-cytokine antibodies, and examined by flow cytometry. For 
analysis of proliferation, cells were surface stained, fixed, permeabilized, stained with anti-
Ki-67 antibody, and examined by flow cytometry. Analysis of flow cytometry samples was 
performed on Becton Dickinson FACSCanto instruments and data were analyzed using 
FACSDiva software (V5.1).
Cryosection immunostaining
Human skin grafts were embedded in OCT, frozen, and stored at −80°C until use. 5-μm 
cryosections were cut, air dried, fixed for 5 min in acetone, rehydrated in PBS, and blocked 
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with 20 μg/ml of human IgG (Jackson ImmunoResearch Laboratories) for 15 min at room 
temperature. Sections were incubated with primary antibody for 30 min, and then rinsed 
three times in PBS/1% BSA for 5 min. If necessary, secondary antibody was added for 30 
min, followed by three rinses. Sections were mounted using Prolong Gold Antifade with 
DAPI (Life Technologies) and examined immediately by immunofluorescence microscopy. 
Antibodies were obtained from the following: Biolegend (CD3, CD69), LifeSpan 
BioSciences (CD103), Abcam (cytokeratin 15) and Jackson Immunoresearch (secondary 
antibodies). Sections were photographed using a microscope (Eclipse 6600; Nikon) 
equipped with a 40×/0.75 objective lens (Plan Fluor; Nikon). Images were captured with a 
camera (SPOT RT model 2.3.1; Diagnostic Instruments) and were acquired with SPOT 4.0.9 
software (Diagnostic Instruments).
Proliferation and cytokine analysis of cells stimulated within explants
Ten mm punch biopsies of healthy adult skin were injected with 100 μl of PBS (control), α-
CD3/α-CD28 antibody mixture (0.5 μg/ml each), or heat-killed Staphylococcus aureus 
(106/ml, ATCC) or Candida albicans (5x103/ml, ATCC). Biopsies were floated in 0.4 μm 
pore size Transwell inserts in X-VIVO 15 medium (Lonza). After 2 weeks cell that had 
migrated out of the biopsies were collected, rested overnight in X-VIVO 15 medium, and 
analyzed for cytokine production and proliferation by flow cytometry as described above. 
Only cells that had migrated out of the explants were analyzed.
In vitro studies of CD103 regulation
To obtain keratinocytes, healthy human skin was separated into epidermis and dermis by 
incubating with 1.4IU /ml of dispase II (Roche) in RPMI (Life Technologies) at 4°C for 12 
hrs. Epidermis was peeled away from the dermis, minced and further digested with 1.4IU/ml 
dispase at 37°C for 30 min, then filtered in a cell strainer. Keratinocytes were cultured to 
confluence in 24-well flat-bottomed plates using keratinocyte-FCM media (Life 
Technologies). To obtain fibroblasts, the dermis was minced, digested with 0.2 % 
collagenase/DNase (Sigma Aldrich) at 37°C for 2 hours, then filtered in a cell strainer. 
Fibroblasts were cultured to confluence in RPMI supplemented with 15% FCS and 10 ng/ml 
EGF. CD3+CD4+ and CD3+CD8+ T cells were isolated using magnetic separation (negative 
isolation kits, Miltenyi Biotec) from healthy human PBMC. CD103 was expressed by a 
mean 3% of the isolated CD8 T cells but otherwise surface expression of CD69 and CD103 
was <1% in these T cell fractions. 1x105 T cells were stimulated with αCD3/CD2/CD28 T 
cell activation beads (Miltenyi Biotec) with 1:2 ratio for 24 hrs (day 0) and then added to 
keratinocytes or fibroblasts monolayers (day 1) in Iscove’s Modified Dulbecco’s Media 
(Corning) supplemented with 10% FCS and L-glutamine. For indirect cultures, transwells 
with 0.4 μm polyester membrane (Corning) were used to separate T cells from fibroblasts 
and keratinocyte monolayers. Neutralizing abs for TGFβ (R & D), E-Cadherin (Millipore), 
LFA-1 (Biolegend) and Integrinβ1 (R & D) and recombinant human TGFβ (R&D) were 
added to co-cultures system with final concentration of 10 μg/ml. T cells were collected by 
washing on day 6 after starting co-culture. Adherent T cells were counted by microscopy 
and collected by incubating the wells with trypsin/EDTA (Gemini Bio-Products) for 5 min 
at 37°C.
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CyTOF mass cytometry analysis of peripheral blood T cells
T cells were isolated from healthy donor PBMC by depletion of non-T cells using the Pan T 
isolation kit and AutoMacs separator (Miltenyi Biotec). T cells were pre-treated with 
TAPI-2 (100 μM, Sigma Aldrich) for 1 hr prior to stimulation and during the 4 hr of 
stimulation with PMA/ionomycin plus brefeldin A to prevent stimulation-induced cleavage 
of L-selectin (35). Following stimulation, T cells were stained with surface marker metal-
conjugated antibodies (MCA, Fluidigm, Inc.) at concentrations found to be effective in prior 
antibody tests. After surface staining, cells were fixed, permeabilized and stained with MCA 
intracellular antibodies for 30 min at room temperature. The cells were then labeled 
overnight at 4°C with 125nM DNA intercalator (Fluidigm, Inc). Finally, the cells were 
diluted to the appropriate concentration in distilled water containing 10% EQ™ Four 
Element Calibration Beads (Fluidigm, Inc) to achieve an acquisition rate <500 events/s on 
the CyTOF2 instrument using the recommended default settings for the CyTOF2 (Fluidigm, 
Inc). CyTOF data were normalized to the beads through the CyTOF2 software after 
acquisition without bead removal and using default settings (Fluidigm, Inc). After built-in 
cell-identifying software created a FCS file, CyTOF data were analyzed in a manner similar 
to standard flow cytometry analysis by FCS express software 4.0 (De Novo Software) using 
DNA content and normalization beads to identify single-cell events.
Statistical analyses
Primary methods of data analysis included descriptive statistics (means, medians and s.d.). 
Differences between two sample groups were detected using the one tailed Wilcoxon–
Mann–Whitney test, α=0.05. For comparisons of multiple groups, a Kruskal–Wallis one-
way analysis of variance with a Bonferroni-Dunn’s post test for multiple means test was 
used, α=0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Skin T cells in a human engrafted mouse model recapitulate T cell populations in adult 
human skin
(A) A human engrafted mouse model was used to discriminate resident from recirculating T 
cells in skin. NSG mice were grafted with human foreskin and injected i.v. with allogeneic 
human PBMC, and alemtuzumab (αCD52) was used to deplete recirculating human T cells 
from grafted human skin. (B–E) human foreskins contained resident APC but few T cells. 
(B) Flow cytometry staining of collagenase digested foreskin demonstrated both CD11c+ 
DC and CD1a+ LC were present in foreskin. (C) Approximately four-fold more DC than T 
cells were present in foreskin, as assayed by the % viable cells of each cell type in 
collagenase digested foreskin. (D) T cells were 45-fold more frequent in healthy adult 
human skin than in foreskins; the percentage of CD3+ T cells in collagenase digested 
foreskin versus adult skin is shown. (E) The few T cells present in human foreskin lacked 
markers characteristic of TRM. The percent of T cells expressing each marker in collagenase 
treated foreskin and adult skin are shown. The mean and SEM of four foreskins (C–E) and 
seven adult skin donors (D,E) are shown (test: T-test). (F–H) allogeneic PBMC injected i.v. 
into grafted mice migrated specifically into the human skin graft and induced an 
inflammatory dermatitis. Images are representative of eight PBMC injected and eight saline 
injected mice. (F) H&E stained section demonstrating the junction between mouse and 
human skin in grafted mice. (G) H&E stain, 20X view of inflammatory dermatitis. (H) A 
cryosections of human grafted skin immunostained for CD3 (red) and keratin (green) are 
shown. T cells were evident in both the dermis and the epidermis. The dermoepidermal 
junction is indicated by a white line. (I) in the absence of infused allogeneic PBMC, no 
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inflammatory infiltrate was observed and few or no T cells were visualized in skin. (J) 
CD69 up-regulation preceded CD103 up-regulation in T cells migrating into human skin 
grafts. Human skin grafts were harvested at the indicated time points, collagenase digested, 
and T cells were analyzed for CD69 and CD103 expression by flow cytometry. The mean 
and SEM of two grafted mice per time point are shown (test: T-test). (K,L) T cell 
populations in grafted skin recapitulate those observed in adult human skin. T cell 
expression of TCM (CCR7/L-selectin) and TRM (CD69/CD103) markers as assayed by flow 
cytometry are shown. T cells were isolated by collagenase digestion from healthy adult 
human skin or from skin grafts on PBMC infused mice. Representative histograms (K) and 
mean and SEM of expression of CD69 and CD103 are shown. The mean and SEM of three 
grafts and seven healthy skin donors are shown (test: T-test).
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Figure 2. Alemtuzumab depletes recicrulating TCM from skin in human engrafted mice but 
spares a population of skin T cells
(A, B) Shown are human T cells isolated from peripheral blood (Blood) and collagenase 
digested foreskin grafts (Skin) stained for CD3 and analyzed by flow cytometry. Samples 
were obtained from human engrafted mice after treatment with either control IgG, 
alemtuzumab (αCD52) or with the anti-CD3-diphtheria immunotoxin A-dmDT(390)-
bisFv(UCHT1) (αCD3-DT). Representative dot plots (A) and aggregate data (B) are shown 
from four control IgG (alemtuzumab control) injected mice, six alemtuzumab injected mice, 
two control IgG (αCD3-DT control) injected mice and two αCD3-DT treated mice. (C) 
CCR7+/L-selectin+ TCM were present in the blood and skin of human engrafted mice and 
were depleted in the skin by alemtuzumab. T cells isolated from the blood and skin of 
control IgG treated mice and the skin of alemtuzumab treated (αCD52) human engrafted 
mice are shown. (D) Aggregate data showing depletion of CCR7+/L-selectin+ TCM in skin 
grafts of human engrafted mice treated with control IgG (−) or alemtuzumab (+). Depletion 
of TCM among the CD3+, CD4+ and CD8+ T cell populations are shown. The mean and 
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SEM of three grafted mice per group are shown. For comparison, the numbers of CCR7+/L-
selectin+ TCM in the skin of five human CTCL patients (CTCL) before (−) and after (+) 
alemtuzumab therapy are shown.
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Figure 3. Distinct populations of non-recirculating CD103+ and CD103− TRM exist in human 
skin engrafted mice and in human skin
(A) TRM cells remaining in the human skin grafts of mice after alemtuzumab treatment 
expressed CD69 and a subset coexpressed CD103. (B) The relative percentages of CD4+ 
and CD8+ T cells in human skin grafts did not change appreciably after alemtuzumab 
treatment. Shown are the percentage of total CD4+and CD8+ T cells in three control IgG 
(cont IgG) and four alemtuzumab (αCD52) treated mice (test: T-test). (C) Most CD4+ TRM 
cells were CD69+/CD103− whereas the majority of CD8+ T cells expressed both CD69 and 
CD103. (D) CD4+/CD69+/CD103− T cells were the most frequent TRM population in 
alemtuzumab treated human engrafted mice. The relative percentages of the indicated TRM 
subsets are shown. (E) CD103+ and CD103− TRM were found in both the epidermis and the 
dermis of human engrafted mice after alemtuzumab treatment. (F) Confirmatory studies in 
human patients demonstrated that CD103+ and CD103− TRM also exist in human skin 
following treatment with alemtuzumab. CD3+ T cells isolated from healthy skin (top row of 
histograms) and the skin of a CTCL patient after alemtuzumab treatment (bottom row of 
histograms) are shown. Similar to the findings in human engrafted mice, CD69 was 
expressed by virtually all TRM, CD4+ and CD8+ TRM of both subsets were observed, and 
CD4+ T cells were more frequently CD103− whereas CD8+ TRM were more frequently 
CD103+. Results are representative of data from three treated patients.
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Figure 4. Two phenotypically and functionally distinct populations of TRM exist in healthy adult 
human skin
(A,B, C) Adult human skin was enzymatically separated into epidermis and dermis, T cells 
were then isolated and analyzed by flow cytometry for the expression of TRM markers CD69 
and CD103. Representative histograms (A) and aggregate data from 5 donors (B, C) are 
shown. The percentages of CD69+/CD103+ (CD103+ TRM), CD69+/CD103− (CD103− TRM) 
and CD69−/CD103− (Recirculating) T cells as a percentage of the separate CD4+ and CD8+ 
subsets are shown in (B) and proportions of each in CD3+ T cells as a whole (C) are shown. 
CD103+ TRM, both CD4+ and CD8+, were most frequent in the epidermis whereas CD103 − 
TRM, in both CD4+ and CD8+ T cells, were more frequent in the dermis. Recirculating T 
cells were the minority among both CD4+ and CD8+ T cell populations in skin. (D) CD103+ 
TRM were superior to other T cell subsets in the production of effector cytokines. Shown are 
the relative production of the indicated effector cytokines by CD69+/CD103+ (CD103+ 
TRM), CD69+/CD103− (CD103− TRM) and CD69−/CD103− (Recirculating) T cells isolated 
from healthy human skin. T cell subsets were isolated from either non-fractionated skin 
(whole skin), the epidermis alone and the dermis alone. The mean and SEM of analyses 
from three donors (whole skin), and five donors (epidermis and dermis) are shown (test:one 
way ANOVA).
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Figure 5. CD103+ TRM have a lower proliferative capacity but increased effector function
Skin explants were injected with PBS, stimulatory anti-CD3and anti-CD28 antibodies 
(αCD3), or heat killed extracts of C. albicans and S. aureus. Two weeks later, T cells that 
had migrated out of the skin were collected and the proliferation of CD4+ TRM (A) and 
CD8+ TRM (C) were assayed by staining for Ki-67 and flow cytometry analysis. TNFα 
production was assayed by intracellular cytokine staining and flow cytometry analysis after 
stimulation with PMA and ionomycin. Results for CD4+ TRM (B) and CD8+ TRM (D) are 
shown. Results are shown for CD69+/CD103+ (CD103+ TRM), and CD69+/CD103− 
(CD103− TRM) The mean and SEM of three donors (PBS) and six donors (all other 
conditions) are shown (test:T-test).
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Figure 6. T cell CD103 induction is enhanced by keratinocyte contact, depends on TGFβ and is 
independent of T cell keratinocyte adhesive interactions
(A,B) In human engrafted mice, T cells that migrating into the epidermis had a higher rate of 
CD103 up-regulation than dermal T cells. (A) Representative immunostains of human 
foreskin skin grafts 3 weeks after IV injection of CD103− PBMC are shown. CD103+ T cells 
were primarily localized to the epidermal compartment. The dermal-epidemal junction is 
highlighted by a white line. (B) The mean and SEM of 8 separate experiments are shown 
(test: T-test). (C) Keratinocyte contact induced up regulation of CD103 in CD4+ T cells 
from human blood stimulated with αCD3/αCD2/αCD28 beads. CD4+ T cells were isolated 
from human peripheral blood by magnetic bead separation and then co-cultured in direct 
contact (direct) with confluent monolayers of human keratinocytes (ker) or fibroblasts (fib) 
or in transwells separated from keratinocyte or fibroblasts monolayers (indirect) for one 
week in the presence of αCD3/αCD2/αCD28 beads. CD103 expression was then assessed 
by immunostaining and flow cytometry anlysis. The mean and SEM of four separate 
experiments are shown (test: ANOVA). (D). Blocking of adhesive interactions with 
keratinocytes had no effect on CD103 upregulation but neutralization of TGFβ did decrease 
CD103 induction. CD4+ T cells were cultured on confluent human keratinocyte monolayers 
for one week in the presence of αCD3/αCD2/αCD28 beads and the indicated control and 
function blocking antibodies. The mean and SEM of four experiments are shown (test: 
ANOVA). (E,F) TGFβ neutralizing antibodies decreased and exogenous TGFβ increased 
CD103 induction. T cells were cultured in transwells across from keratinocyte monolayers 
(E) or indirect contact with keratinocyte monolayers (F) for one week in the presence of 
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αCD3/αCD2/αCD28 beads and the indicated neutralizing TGFβ antibodies (αTGFβ) or 
recombinant human TGFβ (hTGFβ). the mean and SEM of 2 separate experiments are 
shown (test: ANOVA). (G) Function blocking E-cadherin antibodies inhibited T cell 
adhesion to keratinocyte monolayers. CD4+ T cells were cultured on confluent human 
keratinocyte monolayers for one week in the presence of αCD3/αCD2/αCD28 beads in the 
presence of isotype control or E-cadherin function blocking antibodies. Nonadherent T cells 
were removed by rinsing and adherent T cells were then eluted from the wells by treatment 
with trypsin/EDTA. The mean and SEM of the number of adherent cells per well from three 
separate experiments are shown (test:T-test).
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Figure 7. CCR7+/L-selectin− T cells make up a second distinct population of recirculating T cells 
in human skin
(A) CCR7+/L-selectin− T cells were present in healthy human skin and the skin of CTCL 
patients and were depleted by alemtuzumab therapy. (B) The proportion of TMM (CCR7+/L-
selectin−/CD69− T cells) in 10 healthy skin donors (NS) and ten CTCL patients before 
(untx) and after (αCD52) alemtuzumab therapy are shown (test: T-test). (C) TMM are the 
most frequent CLA+ memory T cell population in human blood. The relative percentages of 
CCR7+/L-selectin+ central memory (TCM), CCR7+/L-selectin− migratory memory (TMM), 
and CCR7−/L-selectin− effector memory (TEM) T cells in the CD4+ and CD8+ T cells from 
human peripheral blood are shown. The mean and SEM of four donors are shown. 
Representative histograms are included in Fig. S4. (D) The effector functions of circulating 
TMM are intermediate between those of TCM and TEM. For panels, C and D, T cells were 
isolated from peripheral blood, stimulated with PMA and ionomycin in the presence of an L-
selectin shedding inhibitor, stained for surface markers and intracellularly for cytokine 
production and then analyzed by CyTOF mass spectrometry. The mean and SEM of four 
donors are shown (test: ANOVA).
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Figure 8. In human patients with CTCL, malignant T cells with a TMM phenotype were 
associated with expanding skin lesions with ill-defined borders and were depleted more slowly 
from skin then TCM after alemtuzumab therapy
(A) CTCL patients with malignant T cells of a TCM (CCR7+/L-selectin+) phenotype had 
diffuse erythema of the skin. In contrast, CTCL patients in whom the malignant T cells have 
a TMM phenotype (CCR7+/L-selectin−) in lesional skin (B,C) or blood (D), presented with 
expanding discrete skin lesions with ill-defined borders. (E) A patient who had malignant T 
cells of both TCM and TMM phenotype had both diffuse erythema on presentation as well as 
discrete skin lesions with ill-defined borders. The patient was placed on alemtuzumab 
therapy and the skin was re-biopsied 18 days later. (F) 18 days after alemtuzumab initiation, 
the discrete erythema had receded, leaving the ill-defined skin lesions. Analysis of T cells 
from the skin demonstrated a relative depletion of TCM but persistence of TMM in skin.
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